顶流葛兰，重启限购

Core Viewpoint - Recent announcements from China Europe Fund indicate a trend of limiting large purchases for several high-performing funds, including the China Europe Medical Innovation Fund managed by Ge Lan, which has a daily purchase limit of 100,000 yuan per account [1][3][14]. Fund Purchase Restrictions - Starting from August 11, 2025, the China Europe Medical Innovation Fund will suspend large purchases, conversions, and regular investment plans, with a limit of 100,000 yuan per account [3][5]. - This follows a similar restriction placed on another fund managed by Ge Lan, the China Europe Medical Health Fund, which has maintained a 100,000 yuan limit since January 2021 [1][3]. Fund Performance and Holdings - As of mid-2023, the China Europe Medical Innovation Fund has a total net asset value exceeding 8.2 billion yuan, with significant investments in the healthcare sector, accounting for 46.41% of its portfolio [6][7]. - The top ten holdings of the fund include notable companies such as 3SBio, with a year-to-date increase of nearly 400%, and all top ten stocks have shown an average increase of over 100% this year [6][8][9]. Market Trends and Fund Management - The recent surge in the innovative drug sector has led to a continuous rise in the unit net value of the China Europe Medical Innovation Fund, which recently surpassed 1.7 yuan, compared to a low of 0.9 yuan a year ago [9]. - The trend of limiting purchases is seen across the industry, with approximately 50 actively managed equity funds announcing similar restrictions since July, reflecting a cautious approach by fund managers to maintain investment strategy effectiveness and protect existing investors [14][15].